CAPR News and Press, Capricor Therapeutics Inc. From 04/01/24

2024-04-01 10:17:11 ET More on Solid Biosciences Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid William Blair starts Solid Biosciences at outperform Piper Sandler upgrades Solid Biosciences to overweight Seeking Alpha’s Quant ...

2024-03-22 10:00:33 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Johnson & Johnson, Boston Scientific least shorted stocks in S&...

2024-03-18 12:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-13 13:46:03 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2023 Earnings Call Transcript Biotech And Pharma Diversification Pays Off Catalyst Pharmaceuticals At A Crossroads: Firdapse Litigation And Agamree's Launch Catal...

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month ...

2024-03-05 11:03:07 ET More on Regenxbio REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips Regenxbio Q4 2023 Earnings Preview Regenxbio spikes after trial win for gene therapy in Hu...

-Enrollment Complete in Cohort A of Phase 3, Pivotal, HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy; Announced Successful Interim Futility Analysis; On Track to Report Top-Line Data in Q4 2024- -Upcoming Type-B Meeting with FDA in Q1 2024 to Discuss Commercial Manufacturi...

Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...

SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- – Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company has been granted an in-pers...

2024-02-20 13:15:30 ET More on Capricor Therapeutics Seeking Alpha’s Quant Rating on Capricor Therapeutics Historical earnings data for Capricor Therapeutics Financial information for Capricor Therapeutics Read the full article on Seeking Alpha ...